ANTIBODY RESPONSE TO THE COVID-19 CHADOX1NCOV-19 (ASTRA ZENECA) AND BNT162B (PFIZER) VACCINES AFTER TEMPORARY SUSPENSION OF DMARD THERAPY IN IMMUNE MEDIATED INFLAMMATORY DISEASE (IMID)

Ai Tran

doi:10.26182/cvc4-dn22

ANTIBODY RESPONSE TO THE COVID-19 CHADOX1NCOV-19 (ASTRA ZENECA) AND BNT162B (PFIZER) VACCINES AFTER TEMPORARY SUSPENSION OF DMARD THERAPY IN IMMUNE MEDIATED INFLAMMATORY DISEASE (IMID)

Ai Tran

UWA Medical School

Research output: Thesis › Master's Thesis

52 Downloads (Pure)

Abstract

This study evaluated the antibody responses to the AstraZeneca and Pfizer COVID-19 vaccines in patients with immune mediated inflammatory diseases (IMIDs) on disease-modifying antirheumatic drugs (DMARDs). It compares the effects of continuing versus withholding DMARD therapy post-vaccination. Results indicate that withholding conventional synthetic DMARDs (csDMARD) and targeted DMARDs (tsDMARD) improves seroconversion rates, with those over age 60 benefiting most from pausing csDMARDs. Six months post-vaccination, most remained seropositive, with Pfizer vaccine recipients showing longer antibody persistence. A booster dose restored immunity across all groups, suggesting that pausing certain DMARDs around vaccination enhances immune response, with the Pfizer vaccine offering longer-lasting protection.

Original language	English
Qualification	Masters
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Nossent, Hans, Supervisor Ding, Nik, Supervisor, External person Bell, Damon, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	17 Feb 2024
DOIs	https://doi.org/10.26182/cvc4-dn22
Publication status	Unpublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.26182/cvc4-dn22

THESIS - MASTER OF CLINICAL RESEARCH - TRAN Ai Phuong - 2023
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

2 Article

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)
Tran, A. P., Tassone, D. F., Ding, N. S. & Nossent, J., 2 Mar 2023, In: RMD Open. 9, 1, e002871.
Research output: Contribution to journal › Article › peer-review

Open Access
5 Citations (Scopus)
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)
Tran, A. P., Tassone, D., Nossent, J. & Ding, N. S., 1 May 2022, In: RMD Open. 8, 1
Research output: Contribution to journal › Article › peer-review

Open Access
6 Citations (Web of Science)

Cite this

@mastersthesis{f29ae01b921b48a993cab04fc9792672,

title = "ANTIBODY RESPONSE TO THE COVID-19 CHADOX1NCOV-19 (ASTRA ZENECA) AND BNT162B (PFIZER) VACCINES AFTER TEMPORARY SUSPENSION OF DMARD THERAPY IN IMMUNE MEDIATED INFLAMMATORY DISEASE (IMID)",

abstract = "This study evaluated the antibody responses to the AstraZeneca and Pfizer COVID-19 vaccines in patients with immune mediated inflammatory diseases (IMIDs) on disease-modifying antirheumatic drugs (DMARDs). It compares the effects of continuing versus withholding DMARD therapy post-vaccination. Results indicate that withholding conventional synthetic DMARDs (csDMARD) and targeted DMARDs (tsDMARD) improves seroconversion rates, with those over age 60 benefiting most from pausing csDMARDs. Six months post-vaccination, most remained seropositive, with Pfizer vaccine recipients showing longer antibody persistence. A booster dose restored immunity across all groups, suggesting that pausing certain DMARDs around vaccination enhances immune response, with the Pfizer vaccine offering longer-lasting protection. ",

keywords = "COVID-19, Vaccine, DMARD, Astra Zeneca, Pfizer, Methotrexate, IMID, mRNA",

author = "Ai Tran",

year = "2023",

doi = "10.26182/cvc4-dn22",

language = "English",

school = "The University of Western Australia",

}

TY - THES

T1 - ANTIBODY RESPONSE TO THE COVID-19 CHADOX1NCOV-19 (ASTRA ZENECA) AND BNT162B (PFIZER) VACCINES AFTER TEMPORARY SUSPENSION OF DMARD THERAPY IN IMMUNE MEDIATED INFLAMMATORY DISEASE (IMID)

AU - Tran, Ai

PY - 2023

Y1 - 2023

N2 - This study evaluated the antibody responses to the AstraZeneca and Pfizer COVID-19 vaccines in patients with immune mediated inflammatory diseases (IMIDs) on disease-modifying antirheumatic drugs (DMARDs). It compares the effects of continuing versus withholding DMARD therapy post-vaccination. Results indicate that withholding conventional synthetic DMARDs (csDMARD) and targeted DMARDs (tsDMARD) improves seroconversion rates, with those over age 60 benefiting most from pausing csDMARDs. Six months post-vaccination, most remained seropositive, with Pfizer vaccine recipients showing longer antibody persistence. A booster dose restored immunity across all groups, suggesting that pausing certain DMARDs around vaccination enhances immune response, with the Pfizer vaccine offering longer-lasting protection.

AB - This study evaluated the antibody responses to the AstraZeneca and Pfizer COVID-19 vaccines in patients with immune mediated inflammatory diseases (IMIDs) on disease-modifying antirheumatic drugs (DMARDs). It compares the effects of continuing versus withholding DMARD therapy post-vaccination. Results indicate that withholding conventional synthetic DMARDs (csDMARD) and targeted DMARDs (tsDMARD) improves seroconversion rates, with those over age 60 benefiting most from pausing csDMARDs. Six months post-vaccination, most remained seropositive, with Pfizer vaccine recipients showing longer antibody persistence. A booster dose restored immunity across all groups, suggesting that pausing certain DMARDs around vaccination enhances immune response, with the Pfizer vaccine offering longer-lasting protection.

KW - COVID-19

KW - Vaccine

KW - DMARD

KW - Astra Zeneca

KW - Pfizer

KW - Methotrexate

KW - IMID

KW - mRNA

U2 - 10.26182/cvc4-dn22

DO - 10.26182/cvc4-dn22

M3 - Master's Thesis

ER -

ANTIBODY RESPONSE TO THE COVID-19 CHADOX1NCOV-19 (ASTRA ZENECA) AND BNT162B (PFIZER) VACCINES AFTER TEMPORARY SUSPENSION OF DMARD THERAPY IN IMMUNE MEDIATED INFLAMMATORY DISEASE (IMID)

Abstract

UN SDGs

Access to Document

Fingerprint

Research output

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)

Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)

Cite this